Literature DB >> 12512357

Detection, identification, and subtyping of Actinobacillus pleuropneumoniae.

Joachim Frey1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12512357     DOI: 10.1385/1-59259-344-5:87

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


× No keyword cloud information.
  13 in total

1.  Microbial DNA typing by automated repetitive-sequence-based PCR.

Authors:  Mimi Healy; Joe Huong; Traci Bittner; Maricel Lising; Stacie Frye; Sabeen Raza; Robert Schrock; Janet Manry; Alex Renwick; Robert Nieto; Charles Woods; James Versalovic; James R Lupski
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

2.  Multiplex PCR that can distinguish between immunologically cross- reactive serovar 3, 6, and 8 Actinobacillus pleuropneumoniae strains.

Authors:  L Zhou; S C P Jones; Ø Angen; J T Bossé; J H E Nash; J Frey; R Zhou; H C Chen; J S Kroll; A N Rycroft; P R Langford
Journal:  J Clin Microbiol       Date:  2007-12-19       Impact factor: 5.948

3.  Isolation of an atypical strain of Actinobacillus pleuropneumoniae serotype 1 with a truncated lipopolysaccharide outer core and no O-antigen.

Authors:  Mario Jacques; Josée Labrie; Frank St Michael; Andrew D Cox; Marie-Anne Paradis; C Paul Dick; Christian Klopfenstein; André Broes; Nahuel Fittipaldi; Marcelo Gottschalk
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

4.  A Novel Glaesserella sp. Isolated from Pigs with Severe Respiratory Infections Has a Mosaic Genome with Virulence Factors Putatively Acquired by Horizontal Transfer.

Authors:  Anne E Watt; Glenn F Browning; Alistair R Legione; Rhys N Bushell; Andrew Stent; Ross S Cutler; Neil D Young; Marc S Marenda
Journal:  Appl Environ Microbiol       Date:  2018-05-17       Impact factor: 4.792

5.  The live attenuated Actinobacillus pleuropneumoniae triple-deletion mutant ΔapxIC ΔapxIIC ΔapxIV-ORF1 strain, SLW05, Immunizes pigs against lethal challenge with Haemophilus parasuis.

Authors:  Shulin Fu; Jiwen Ou; Minmin Zhang; Juan Xu; Huazhen Liu; Jinlin Liu; Fangyan Yuan; Huanchun Chen; Weicheng Bei
Journal:  Clin Vaccine Immunol       Date:  2012-12-05

6.  Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.

Authors:  Ciaragh O'Neilla; Sophie C P Jones; Janine T Bossé; Conrad M Watson; Susanna M Williamson; Andrew N Rycroft; J Simon Kroll; Helen M Hartley; Paul R Langford
Journal:  Vaccine       Date:  2010-05-16       Impact factor: 3.641

7.  Comparative profiling of the transcriptional response to iron restriction in six serotypes of Actinobacillus pleuropneumoniae with different virulence potential.

Authors:  Kirstine Klitgaard; Carsten Friis; Oystein Angen; Mette Boye
Journal:  BMC Genomics       Date:  2010-12-09       Impact factor: 3.969

8.  Randomised controlled field study to evaluate the efficacy and clinical safety of a single 8 mg/kg injectable dose of marbofloxacin compared with one or two doses of 7.5 mg/kg injectable enrofloxacin for the treatment of Actinobacillus pleuropneumoniae infections in growing-fattening pigs in Europe.

Authors:  Erik Grandemange; Pierre-Alexandre Perrin; Dejean Cvejic; Miriam Haas; Tim Rowan; Klaus Hellmann
Journal:  Porcine Health Manag       Date:  2017-05-10

9.  Detection of Actinobacillus Pleuropneumoniae ApxIV Toxin Antibody in Serum and Oral Fluid Specimens from Pigs Inoculated Under Experimental Conditions.

Authors:  Wendy González; Luis G Giménez-Lirola; Ashley Holmes; Sergio Lizano; Christa Goodell; Korakrit Poonsuk; Panchan Sitthicharoenchai; Yaxuan Sun; Jeffrey Zimmerman
Journal:  J Vet Res       Date:  2017-12-06       Impact factor: 1.744

10.  Evaluation of the predictive value of tonsil examination by bacteriological culture for detecting positive lung colonization status of nursery pigs exposed to Actinobacillus pleuropneumoniae by experimental aerosol infection.

Authors:  Doris Hoeltig; Florian Nietfeld; Katrin Strutzberg-Minder; Judith Rohde
Journal:  BMC Vet Res       Date:  2018-06-28       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.